Paradromics is an Invasive Cortical Implants company founded in 2015 and based in Austin, United States. It has raised $53M in total funding, most recently a Series A in 2023.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| May 1, 2023 | Series A | $33M | — | Prime Movers Lab |
| Jul 1, 2021 | Seed | $20M | — | Prime Movers Lab |
Paradromics receives FDA approval to expand recruitment for its brain implant clinical study.

Paradromics receives FDA approval to expand recruitment for its Connexus brain-computer interface clinical study nationwide.
Paradromics and Siemens Healthineers partner to build an advanced imaging foundation supporting brain-computer interfaces.

Paradromics and Siemens Healthineers partner to improve BCI implant targeting accuracy.
A fully-implantable high-density cortical BCI with up to 1,684 platinum-iridium microwire electrodes across four cortical modules, designed for speech and communication restoration in people with ALS, spinal cord injury, or stroke. Targets 200+ bits-per-second neural data throughput—industry-leading in pre-clinical models. Received FDA IDE approval for the Connect-One early feasibility study in November 2025; first-in-human implant completed June 2026 at the University of Michigan (Connect-One study).
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗